{"classes":[{"categories":[{"measurements":[{"comment":"The study was ended prematurely due to poor accrual and only two patients progressed while the rest were lost to follow up. The statistical analysis will not give a reliable range except median based on two findings","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"The duration of time from the start of treatment to the first documentation of tumor progression.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.\n\nPembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"Since the trial stopped due to poor accrual, and more censored patients, the 95% CI for median PFS and OS could not be determined. We are reporting median values without CI.","reportingStatus":"POSTED","timeFrame":"Baseline up to two years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"days"}